AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30899835 — intervention group
Group type: COMPARATOR
Intervention: N-S (needle-syringe)
Number of subjects: 128
Study 30900412 — intervention group
Group type: EXPERIMENTAL
Intervention: Prepregnancy BMI
Number of subjects: 135
Study 30900412 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational weight gain
Number of subjects: 135
Study 30900412 — intervention group
Group type: EXPERIMENTAL
Intervention: Postpartum weight loss
Number of subjects: 135
Study 30900412 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose challenge test results
Number of subjects: 135
Study 30900412 — intervention group
Group type: EXPERIMENTAL
Intervention: Time interaction for insulin
Number of subjects: 135
Study 30900412 — intervention group
Group type: EXPERIMENTAL
Intervention: Time interaction for adiponectin
Number of subjects: 135
Study 30900994 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care STI screening every 4 months for 24 months, including rapid HIV, syphilis, Chlamydia trachomatis, Neisseria gonorrhoeae, and Hepatitis C virus testing.
Number of subjects: 1720
Study 30901746 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic surgery
Number of subjects: 260
Study 30901746 — intervention group
Group type: COMPARATOR
Intervention: Microscopic surgery
Number of subjects: 260
Study 30901746 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 260
Study 30901867 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg ondansetron
Number of subjects: 1287
Study 30901867 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg dexamethasone
Number of subjects: 1287
Study 30901867 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 4 mg ondansetron and 4 mg dexamethasone
Number of subjects: 1287
Study 30901867 — intervention group
Group type: COMPARATOR
Intervention: Control arm (placebo)
Number of subjects: 1287
Study 30901876 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative chemotherapy
Number of subjects: 32
Study 30902090 — intervention group
Group type: EXPERIMENTAL
Intervention: Centiloid cut-off of 12 CL
Number of subjects: 516
Study 30902090 — intervention group
Group type: EXPERIMENTAL
Intervention: Centiloid cut-off of 30 CL
Number of subjects: 516
Study 30902090 — intervention group
Group type: EXPERIMENTAL
Intervention: Centiloid cut-offs in the range of 25-35
Number of subjects: 516
Study 30902361 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal hydromorphone (0.03 mg/kg initial dose, additional 0.015 mg/kg if needed)
Number of subjects: 35
Study 30902361 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal hydromorphone
Number of subjects: 35
Study 30902630 — intervention group
Group type: EXPERIMENTAL
Intervention: BCI-FES
Number of subjects: 1
Study 30902689 — intervention group
Group type: EXPERIMENTAL
Intervention: Text message (TM) alert system and bystander CPR (part of a bundle intervention)
Number of subjects: 3194
Study 30902907 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor Function Measure 32 total score
Number of subjects: 45
Study 30902907 — intervention group
Group type: EXPERIMENTAL
Intervention: Grip and pinch strengths
Number of subjects: 45
Study 30902907 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced vital capacity, forced expiratory volume in the first second of exhalation, and peak cough flow measures
Number of subjects: 45
Study 30902907 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-adeno-associated virus type 8 neutralizing activity
Number of subjects: 45
Study 30902915 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab (PD-L1 inhibition) with paclitaxel and carboplatin, radiotherapy
Number of subjects: 2
Study 30902915 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel (chemotherapy)
Number of subjects: 2
Study 30902915 — intervention group
Group type: COMPARATOR
Intervention: Atezolizumab (PD-L1 inhibition)
Number of subjects: 2
Study 30903140 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant lapatinib plus trastuzumab
Number of subjects: 56
Study 30903140 — intervention group
Group type: COMPARATOR
Intervention: HER2 ratio <4 and/or CN <10
Number of subjects: 56
Study 30903140 — intervention group
Group type: EXPERIMENTAL
Intervention: HER2 ratio ≥4 and/or CN ≥10
Number of subjects: 56
Study 30903140 — intervention group
Group type: EXPERIMENTAL
Intervention: High PTEN or wild-type PIK3CA (intact PI3K pathway)
Number of subjects: 56
Study 30903140 — intervention group
Group type: EXPERIMENTAL
Intervention: HER2 ratio ≥4 and intact PI3K pathway
Number of subjects: 56
Study 30903175 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous hybrid coronary revascularization (sHCR)
Number of subjects: 50
Study 30903175 — intervention group
Group type: COMPARATOR
Intervention: Conventional coronary artery bypass grafting (CABG)
Number of subjects: 50
Study 30903184 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal OSA
Number of subjects: 53
Study 30903275 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib (800 mg orally QD)
Number of subjects: 20
Study 30903647 — intervention group
Group type: EXPERIMENTAL
Intervention: IMPROD biparametric prostate MRI (bpMRI)
Number of subjects: 64
Study 30903647 — intervention group
Group type: EXPERIMENTAL
Intervention: IMPROD bpMRI with 3D dilation of manual cancer delineations
Number of subjects: 64
Study 30903661 — intervention group
Group type: EXPERIMENTAL
Intervention: Plans to keep pills
Number of subjects: 217
Study 30903661 — intervention group
Group type: COMPARATOR
Intervention: Plans to dispose of pills
Number of subjects: 217
Study 30904017 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnancy-related food taboos (PRFT) adherence among anemic women (n=187)
Number of subjects: 592
Study 30904017 — intervention group
Group type: COMPARATOR
Intervention: Pregnancy-related food taboos (PRFT) adherence among non-anemic women (n=405)
Number of subjects: 592
Study 30904017 — intervention group
Group type: EXPERIMENTAL
Intervention: Association of PRFT with anemia
Number of subjects: 592
Study 30904021 — intervention group
Group type: EXPERIMENTAL
Intervention: myo-inositol (1.75 g/day), D-chiro-inositol (0.25 g/day), glucomannan (4 g/day) for 3 months
Number of subjects: 15
Study 30904021 — intervention group
Group type: EXPERIMENTAL
Intervention: myo-inositol, D-chiro-inositol, glucomannan
Number of subjects: 15
Study 30904021 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 15
Study 30904064 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone up to 25 mg/d
Number of subjects: 0
Study 30904228 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person classes focusing on a plant-based diet rich in anti-inflammatory foods, duration: 12 months.
Number of subjects: 95
Study 30904228 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving newsletters, duration: 12 months.
Number of subjects: 95
Study 30904580 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to Alternaria fungal spores in the classroom
Number of subjects: 280
Study 30904580 — intervention group
Group type: COMPARATOR
Intervention: Control group (sensitized but not exposed to Alternaria)
Number of subjects: 280
Study 30904742 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased plasma level of Lp-PLA2
Number of subjects: 1452
Study 30904742 — intervention group
Group type: EXPERIMENTAL
Intervention: Lp-PLA2
Number of subjects: 1452
Study 30904743 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-line glucose-lowering therapy
Number of subjects: 15992
Study 30904830 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate administration
Number of subjects: 0
Study 30904830 — intervention group
Group type: EXPERIMENTAL
Intervention: Seasonal influenza vaccination
Number of subjects: 0
Study 30904854 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based, therapist-guided cognitive-behavioural therapy (CBT) for BDD, 12-week treatment consisting of eight treatment modules.
Number of subjects: 32
Study 30904859 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose chest CT lung cancer screening
Number of subjects: 0
Study 30904869 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-course radiotherapy (SCRT) at dose levels of 6Gy×5F, 7Gy×5F, 8Gy×5F followed by four cycles of modified FOLFOX6 (mFOLFOX6) chemotherapy as neoadjuvant therapy.
Number of subjects: 0
Study 30904869 — intervention group
Group type: COMPARATOR
Intervention: Short-course radiotherapy (SCRT) (25 Gy over five fractions) followed immediately by surgery.
Number of subjects: 0
Study 30904980 — intervention group
Group type: EXPERIMENTAL
Intervention: Pralatrexate IV 30 mg/m²
Number of subjects: 71
Study 30905354 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA) every 3 months until complete remission (CR)
Number of subjects: 78
Study 30905354 — intervention group
Group type: EXPERIMENTAL
Intervention: RFA for treatment of flat USLs
Number of subjects: 78
Study 30905354 — intervention group
Group type: EXPERIMENTAL
Intervention: Pink-color sign at baseline
Number of subjects: 78
Study 30905623 — intervention group
Group type: EXPERIMENTAL
Intervention: Later bedtime
Number of subjects: 87
Study 30905623 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal sleep time
Number of subjects: 87
Study 30905623 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep time and later bedtime
Number of subjects: 87
Study 30906106 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional Brownian motion combined with moving linear regression
Number of subjects: 42418
Study 30906106 — intervention group
Group type: COMPARATOR
Intervention: Classic Brownian motion
Number of subjects: 42418
Study 30906291 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster vaccination with GVGH
Number of subjects: 0
Study 30906291 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 30906596 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week resistance exercise program
Number of subjects: 0
Study 30906596 — intervention group
Group type: COMPARATOR
Intervention: Normal weight participants
Number of subjects: 0
Study 30906596 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese participants
Number of subjects: 0
Study 30906694 — intervention group
Group type: COMPARATOR
Intervention: Gambling intervention only (G only)
Number of subjects: 214
Study 30906694 — intervention group
Group type: EXPERIMENTAL
Intervention: Gambling intervention with mental health intervention (G + MH)
Number of subjects: 214
Study 30906874 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment
Number of subjects: 488
Study 30906874 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 488
Study 30906874 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 488
Study 30907259 — intervention group
Group type: EXPERIMENTAL
Intervention: EndoAnchor implants with good penetration
Number of subjects: 54
Study 30907261 — intervention group
Group type: EXPERIMENTAL
Intervention: Glasgow Outcome Scale-Extended (GOSE)
Number of subjects: 0
Study 30907453 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-staphylococcal treatment
Number of subjects: 20
Study 30907453 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 20
Study 30907508 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV self-testing (HIVST) kits distributed
Number of subjects: 175683
Study 30907744 — intervention group
Group type: EXPERIMENTAL
Intervention: Values-affirmation writing exercise
Number of subjects: 1130
Study 30907744 — intervention group
Group type: COMPARATOR
Intervention: Control writing exercise
Number of subjects: 1130
Study 30907811 — intervention group
Group type: EXPERIMENTAL
Intervention: Free abdominal flaps
Number of subjects: 30
Study 30907859 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous-image contact lenses (prototype and commercially available)
Number of subjects: 141
Study 30907859 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall vision satisfaction ratings
Number of subjects: 141
Study 30907859 — intervention group
Group type: EXPERIMENTAL
Intervention: Vision stability ratings (daytime)
Number of subjects: 141
Study 30907859 — intervention group
Group type: EXPERIMENTAL
Intervention: Other subjective ratings
Number of subjects: 141
Study 30908579 — intervention group
Group type: EXPERIMENTAL
Intervention: Allodynography
Number of subjects: 12
Study 30908927 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Forced Expiratory Volume in 1 Second and Forced Vital Capacity Bronchodilator Response
Number of subjects: 0
Study 30908927 — intervention group
Group type: EXPERIMENTAL
Intervention: Exacerbations
Number of subjects: 0
Study 30908927 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality
Number of subjects: 0
Study 30909729 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher stressful life events (highest versus lowest quartile) at age 55
Number of subjects: 10785
Study 30909729 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher stressful life events (highest versus lowest quartile) at age 65
Number of subjects: 10785
Study 30909729 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher stressful life events in multivariable-adjusted models (sub-cohort with updated measures)
Number of subjects: 10785
Study 30909729 — intervention group
Group type: EXPERIMENTAL
Intervention: Social strain
Number of subjects: 10785
Study 30909729 — intervention group
Group type: EXPERIMENTAL
Intervention: Resilience
Number of subjects: 10785
Study 30909832 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranolazine 500 mg
Number of subjects: 8
Study 30909832 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranolazine 1000 mg
Number of subjects: 8
Study 30909922 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DP)
Number of subjects: 333
Study 30909922 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate-amodiaquine (ASAQ)
Number of subjects: 333
Study 30909922 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 333
Study 30910003 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative indwelling urinary catheterisation
Number of subjects: 795
Study 30910221 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone treatment (mean dose: 0.4mg/kg/week at month 0, M12, M24; 0.3mg/kg/week at M36)
Number of subjects: 98
Study 30910221 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone treatment
Number of subjects: 98
Study 30910346 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab 1200mg every 3 weeks until progression or unacceptable toxicity
Number of subjects: 1004
Study 30910709 — intervention group
Group type: EXPERIMENTAL
Intervention: PARAD+ discrimination algorithm
Number of subjects: 1013
Study 30910890 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-based dosing guidelines for antituberculosis drugs
Number of subjects: 268
Study 30910890 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose increment of one fixed-dose combination (FDC) tablet for weight bands of 30 to 37 and 38 to 54 kg
Number of subjects: 268
Study 30910890 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant use of efavirenz
Number of subjects: 268
Study 30910890 — intervention group
Group type: EXPERIMENTAL
Intervention: Different formulations of rifampin and isoniazid
Number of subjects: 268
Study 30910890 — intervention group
Group type: EXPERIMENTAL
Intervention: Current dosing guidelines
Number of subjects: 268
Study 30910890 — intervention group
Group type: EXPERIMENTAL
Intervention: Adding one FDC tablet to current weight band-based dosing
Number of subjects: 268
Study 30910890 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower isoniazid exposures due to efavirenz
Number of subjects: 268
Study 30910891 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous rifampin, 8 mg/kg for <14 days PNA, 15 mg/kg for ≥14 days PNA, administered once daily
Number of subjects: 27
Study 30910892 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous and oral fluconazole
Number of subjects: 75
Study 30911064 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal acetaminophen use (any use)
Number of subjects: 2291
Study 30911064 — intervention group
Group type: COMPARATOR
Intervention: No prenatal acetaminophen use
Number of subjects: 2291
Study 30911405 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning (RIC) administered by EMS paramedics using the autoRIC® device, 4 cycles of 5-min inflation and 5-min deflation of an upper arm cuff
Number of subjects: 50
Study 30911405 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative data collection from study participants and paramedics regarding study procedures
Number of subjects: 50
Study 30911655 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant PIPAC-directed therapy with oxaliplatin (92 mg/m2)
Number of subjects: 60
Study 30911655 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant PIPAC-directed therapy
Number of subjects: 60
Study 30911655 — intervention group
Group type: EXPERIMENTAL
Intervention: PIPAC-directed therapy
Number of subjects: 60
Study 30911657 — intervention group
Group type: EXPERIMENTAL
Intervention: ABP (Abraxane™) administered via pressurized intraperitoneal aerosol chemotherapy (PIPAC) at escalating doses from 35 to 140 mg/m², with three treatments at 4-week intervals.
Number of subjects: 0
Study 30911656 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) using doxorubicin (1.5 mg/m²) in series of three procedures
Number of subjects: 0
Study 30911656 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC)
Number of subjects: 0
Study 30911656 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI as a staging and response evaluation tool
Number of subjects: 0
Study 30911663 — intervention group
Group type: EXPERIMENTAL
Intervention: PIPAC with oxaliplatin (starting dose 45 mg/m)
Number of subjects: 0
Study 30911664 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaliplatin administered by the intraperitoneal route (PIPAC) at a starting dose of 90 mg/m², during two consecutive procedures at a 4-6 week interval.
Number of subjects: 0
Study 30911664 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaliplatin via PIPAC
Number of subjects: 0
Study 30911664 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose oxaliplatin during PIPAC
Number of subjects: 0
Study 30911669 — intervention group
Group type: EXPERIMENTAL
Intervention: PIPAC C/D (cisplatin and doxorubicin)
Number of subjects: 41
Study 30911669 — intervention group
Group type: EXPERIMENTAL
Intervention: PIPAC OX (oxaliplatin)
Number of subjects: 41
Study 30911669 — intervention group
Group type: COMPARATOR
Intervention: PIPAC OX
Number of subjects: 41
Study 30911669 — intervention group
Group type: EXPERIMENTAL
Intervention: PIPAC procedure
Number of subjects: 41
Study 30911859 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab + chemotherapy (200 mg on day 1, cisplatin 80 mg/m)
Number of subjects: 56
Study 30911859 — intervention group
Group type: COMPARATOR
Intervention: Pembrolizumab (monotherapy)
Number of subjects: 56
Study 30911926 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-pulsed fidaxomicin (EPFX) 200 mg twice daily (days 1-5); once daily on alternate days (days 7-25)
Number of subjects: 356
Study 30911926 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin 125 mg four times daily (days 1-10)
Number of subjects: 356
Study 30911926 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-pulsed fidaxomicin (EPFX)
Number of subjects: 356
Study 30911926 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 356
Study 30912033 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg
Number of subjects: 65
Study 30912033 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg
Number of subjects: 65
Study 30912699 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilotinib 300 mg twice daily
Number of subjects: 128
Study 30912761 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 0
Study 30912761 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Continuous Training (MICT)
Number of subjects: 0
Study 30912761 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief exercise counseling combined with HIIT or MICT
Number of subjects: 0
Study 30912762 — intervention group
Group type: EXPERIMENTAL
Intervention: My JAKE app
Number of subjects: 144
Study 30913032 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous adipose tissue (SAT) distribution measurements at 15 standardized locations
Number of subjects: 375
Study 30913032 — intervention group
Group type: EXPERIMENTAL
Intervention: Nuchal and hip SAT thickness measurements
Number of subjects: 375
Study 30913032 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation analysis of RTL with body fat parameters
Number of subjects: 375
Study 30913226 — intervention group
Group type: EXPERIMENTAL
Intervention: Posaconazole oral suspension 12 mg/kg/day BID
Number of subjects: 0
Study 30913226 — intervention group
Group type: EXPERIMENTAL
Intervention: Posaconazole oral suspension 18 mg/kg/day TID
Number of subjects: 0
Study 30913226 — intervention group
Group type: EXPERIMENTAL
Intervention: Posaconazole oral suspension 18 mg/kg/day BID
Number of subjects: 0
Study 30913226 — intervention group
Group type: EXPERIMENTAL
Intervention: Posaconazole oral suspension 12 mg/kg/day BID, 18 mg/kg/day BID, and 18 mg/kg/day TID
Number of subjects: 0
Study 30913226 — intervention group
Group type: EXPERIMENTAL
Intervention: Posaconazole oral suspension
Number of subjects: 0
Study 30914274 — intervention group
Group type: EXPERIMENTAL
Intervention: FSH treatment (3-6 hours)
Number of subjects: 335
Study 30914274 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated FSH (>11 U/L) in infertile men
Number of subjects: 335
Study 30914274 — intervention group
Group type: EXPERIMENTAL
Intervention: Men with prediabetes
Number of subjects: 335
Study 30914274 — intervention group
Group type: EXPERIMENTAL
Intervention: FSH levels
Number of subjects: 335
Study 30914909 — intervention group
Group type: EXPERIMENTAL
Intervention: XNKQ acupuncture (manual needle-stimulation on five acupuncture points: DU26 unilaterally, PC6, and SP6 bilaterally)
Number of subjects: 24
Study 30914909 — intervention group
Group type: COMPARATOR
Intervention: Needle-stimulation on non-acupuncture points (manual needle-stimulation on five nearby non-acupuncture points)
Number of subjects: 24
Study 30914909 — intervention group
Group type: COMPARATOR
Intervention: Insertion of needles on the XNKQ acupuncture points without stimulation
Number of subjects: 24